Nonribosomal Peptides from Marine Microbes and Their Antimicrobial and Anticancer Potential

Abstract

Marine environments are largely unexplored and can be a source of new molecules for the treatment of many diseases such as malaria, cancer, tuberculosis, HIV etc. The Marine environment is one of the untapped bioresource of getting pharmacologically active nonribosomal peptides (NRPs). Bioprospecting of marine microbes have achieved many remarkable milestones in pharmaceutics. Till date, more than 50% of drugs which are in clinical use belong to the nonribosomal peptide or mixed polyketide-nonribosomal peptide families of natural products isolated from marine bacteria, cyanobacteria and fungi. In recent years large numbers of nonribosomal have been discovered from marine microbes using multi-disciplinary approaches. The present review covers the NRPs discovered from marine microbes and their pharmacological potential along with role of genomics, proteomics and bioinformatics in discovery and development of nonribosomal peptides drugs.

Sponge-associated fungi from a mangrove habitat in Indonesia: species composition, antimicrobial activity, enzyme screening and bioactive profiling

“…The presence of NRPS genes in Eutypella sp. SPMKF 4, L. theobromae SPMKF 5, and F. solani SPMKF 8 raises a presumption that the isolates produce nonribosomal peptides compounds which contribute to antimicrobial property (Agrawal et al 2017). To prove this hypothesis, isolation of antimicrobial compounds through bio-guided isolation protocol is essential to be done.…”

The Biotechnological Potential of Secondary Metabolites from Marine Bacteria

“…Each family is subdivided into homologous subfamilies depending on the position of a certain amino acid in the peptide ring [66,68]. The examples of well-characterized lipopeptide antibiotics, which are metabolites of marine bacteria, are tauromamid, halobacillin and methylhalobacillin [4,[30][31][32].…”

“…Tauromamid is a relatively new non-ribosomally biosynthesized antibiotic [30,31] (Table 2), belonging to the group of cyclic lipopeptides (like daptomycin, the first permitted antibiotic of this class). It is produced by the marine bacterial isolate of Brevibacillus lateosporus PNG276, inhabiting the Gulf of Papua [31].…”

“…Tauromamid is a relatively new non-ribosomally biosynthesized antibiotic [30,31] (Table 2), belonging to the group of cyclic lipopeptides (like daptomycin, the first permitted antibiotic of this class). It is produced by the marine bacterial isolate of Brevibacillus lateosporus PNG276, inhabiting the Gulf of Papua [31]. Tauromamid has a strong and selective inhibitory action on the Gram-positive pathogen Enterococcus sp., as well as exhibiting unexpressed activity against the methicillin-resistant Staphylococcus aureus (MRSA; MIC = 200 µg/mL) and Candida albicans (MIC = 50 µg/mL) [30,31].…”

“…It is produced by the marine bacterial isolate of Brevibacillus lateosporus PNG276, inhabiting the Gulf of Papua [31]. Tauromamid has a strong and selective inhibitory action on the Gram-positive pathogen Enterococcus sp., as well as exhibiting unexpressed activity against the methicillin-resistant Staphylococcus aureus (MRSA; MIC = 200 µg/mL) and Candida albicans (MIC = 50 µg/mL) [30,31].…”